Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

Introduction: The safety and effectiveness of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in clinical trials. However, due to the limitations of these trials, it is important to know how the condition behaves under long-term clinical practice cond...

Full description

Bibliographic Details
Main Authors: A. Pato Pato, E. Costa Arpín, A. Rodríguez Regal, I. Rodríguez Constenla, I. Cimas Hernando, I. Muñoz Pousa, L. Naya Ríos, J.R. Lorenzo González, M.C. Amigo Jorrín, J.M. Prieto González
Format: Article
Language:English
Published: Elsevier España 2021-06-01
Series:Neurología (English Edition)
Subjects:
Eficacia
Esclerosis múltiple
Natalizumab
No evidencia enfermedad activa
Online Access:http://www.sciencedirect.com/science/article/pii/S2173580820300055

Internet

http://www.sciencedirect.com/science/article/pii/S2173580820300055

Similar Items